Brain Neoplasms

• 

  Subject Areas on Research

  • "Extraoperative" MRI (eoMRI) for Brain Tumor Surgery: Initial Results at a Single Institution. 
  • (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes. 
  • (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. 
  • 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. 
  • 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. 
  • 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. 
  • 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. 
  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. 
  • 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. 
  • A Deep Learning-Based Computer Aided Detection (CAD) System for Difficult-to-Detect Brain Metastases. 
  • A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. 
  • A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 
  • A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. 
  • A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. 
  • A broad perspective on evaluating bias in the neuro-oncology workplace. 
  • A case of Ollier's disease associated with two intracranial gliomas. 
  • A case study comparing the relative benefit of optimizing beam weights, wedge angles, beam orientations and tomotherapy in stereotactic radiotherapy of the brain. 
  • A child with refractory complex partial seizures, right temporal ganglioglioma, contralateral continuous electrical status epilepticus, and a secondary Landau-Kleffner autistic syndrome. 
  • A comparative study of brain tumor cells from different age and anatomical locations using 3D biomimetic hydrogels. 
  • A comparison of three stereotactic radiotherapy techniques; ARCS vs. noncoplanar fixed fields vs. intensity modulation. 
  • A comprehensive outlook on intracerebral therapy of malignant gliomas. 
  • A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. 
  • A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats. 
  • A convolutional neural network to filter artifacts in spectroscopic MRI. 
  • A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. 
  • A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? 
  • A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. 
  • A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. 
  • A fully automatic extraction of magnetic resonance image features in glioblastoma patients. 
  • A genetic variant in the APE1/Ref-1 gene promoter -141T/G may modulate risk of glioblastoma in a Chinese Han population. 
  • A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma. 
  • A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. 
  • A hyperspectral imaging system for in vivo optical diagnostics. Hyperspectral imaging basic principles, instrumental systems, and applications of biomedical interest. 
  • A locus for cerebral cavernous malformations maps to chromosome 7q in two families. 
  • A mechanism underlying the lack of a blood-brain barrier to peroxidase in virally induced brain tumors. 
  • A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice. 
  • A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. 
  • A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. 
  • A nomogram for individualized estimation of survival among patients with brain metastasis. 
  • A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. 
  • A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. 
  • A novel method for volumetric MRI response assessment of enhancing brain tumors. 
  • A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. 
  • A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. 
  • A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. 
  • A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. 
  • A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. 
  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. 
  • A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. 
  • A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. 
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 
  • A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A pial window model for the intracranial study of human glioma microvascular function. 
  • A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. 
  • A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. 
  • A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. 
  • A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. 
  • A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. 
  • A precision 3D conformal treatment technique in rats: Application to whole-brain radiotherapy with hippocampal avoidance. 
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. 
  • A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. 
  • A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. 
  • A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 
  • A retrospective analysis of a remifentanil/propofol general anesthetic for craniotomy before awake functional brain mapping. 
  • A review of glioblastoma immunotherapy. 
  • A review of stereotactic radiosurgery in the management of brain metastases. 
  • A statin-regulated microRNA represses human c-Myc expression and function. 
  • A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. 
  • A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma. 
  • ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. 
  • ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. 
  • ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. 
  • ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. 
  • AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival. 
  • AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization. 
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. 
  • Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. 
  • Acidic stress promotes a glioma stem cell phenotype. 
  • Acquired stuttering due to recurrent anaplastic astrocytoma. 
  • Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. 
  • Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. 
  • Acute leukemia following treatment of malignant glioma. 
  • Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine. 
  • Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. 
  • Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. 
  • Adjustment of caregivers of pediatric patients with brain tumors: a cross-sectional analysis. 
  • Adoptive immunotherapy for malignant glioma. 
  • Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. 
  • Adult atypical teratoid/rhabdoid tumor (AT/RT): A case of mistaken identity. 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Advances in the treatment of malignant gliomas. 
  • Advances in treatment techniques: arc-based and other intensity modulated therapies. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 
  • Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. 
  • Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. 
  • Algorithms and functionality of an intensity modulated radiotherapy optimization system. 
  • Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. 
  • Alterations of the TP53 gene in human gliomas. 
  • Alternating Electric Fields for the Treatment of Glioblastoma. 
  • Ambulatory use of high-dose intravenous morphine for severe pain. 
  • American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. 
  • An Analysis of Public Interest in Elective Neurosurgical Procedures During the COVID-19 Pandemic Through Online Search Engine Trends. 
  • An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. 
  • An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. 
  • An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. 
  • An Unusual Ganglioglioma with Pseudopapillary Features and PRKAR2B-BRAF Fusion. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • An image-guided technique for planning and verification of supine craniospinal irradiation. 
  • An improved method of preparing Schmidt-Ruppin Rous sarcoma virus for brain tumor induction in mammals. 
  • An integrated genomic analysis of human glioblastoma multiforme. 
  • An integrated risk model stratifying seizure risk following brain tumor resection among seizure-naive patients without antiepileptic prophylaxis. 
  • Anaplastic human gliomas grown in athymic mice. Morphology and glial fibrillary acidic protein expression. 
  • Angiocentric glioma-like tumor of the midbrain. 
  • Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Anti-angiogenic therapy for high-grade glioma. 
  • Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 
  • Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer. 
  • Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. 
  • Antiangiogenic therapy for high-grade glioma. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Antibody-based immunotherapy for malignant glioma. 
  • Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. 
  • Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. 
  • Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. 
  • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. 
  • Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. 
  • Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. 
  • Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Applications of nanotechnology to imaging and therapy of brain tumors. 
  • Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. 
  • Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. 
  • Arteriovenous malformation mimicking recurrent medulloblastoma. 
  • Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. 
  • Assessing neurocognitive dysfunction in cranial radiotherapy: can cognitive event-related potentials help? 
  • Assessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy. 
  • Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. 
  • Assessment of intra-observer variability in measurement of high-grade brain tumors. 
  • Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. 
  • Assessment of type of allergy and antihistamine use in the development of glioma. 
  • Association and interactions between DNA repair gene polymorphisms and adult glioma. 
  • Association between body mass index and mortality in patients with glioblastoma mutliforme. 
  • Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. 
  • Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study. 
  • Association of preoperative depression and survival after resection of malignant brain astrocytoma. 
  • Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. 
  • Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. 
  • Attitudes toward neurosurgery in a low-income country: a qualitative study. 
  • Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. 
  • Automating neurosurgical tumor resection surgery: Volumetric laser ablation of cadaveric porcine brain with integrated surface mapping. 
  • Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. 
  • Avastin: more questions than answers. . 
  • Awake spinal anesthesia facilitates spine surgery in poor surgical candidates: A case series. 
  • B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. 
  • BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. 
  • BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. 
  • BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior. 
  • Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and daily temozolomide for recurrent glioblastoma. 
  • Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? 
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 
  • Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab therapy for glioblastoma: a passionate discussion. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. 
  • Bevacizumab: radiation combination produces restricted diffusion on brain MRI. 
  • Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. 
  • Bidimensional measurements in brain tumors: assessment of interobserver variability. 
  • Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. 
  • Biology of gliomas: potential clinical implications of glioma cellular heterogeneity. 
  • Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. 
  • Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. 
  • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. 
  • Brain Metastases From Melanoma: Therapy at the Crossroads. 
  • Brain Metastases in Lung Cancer With Targetable Mutations-Reply. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? 
  • Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. 
  • Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. 
  • Brain and other central nervous system tumor statistics, 2021. 
  • Brain and spine imaging findings in AIDS patients. 
  • Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. 
  • Brain cancer stem cells display preferential sensitivity to Akt inhibition. 
  • Brain immunology and immunotherapy in brain tumours. 
  • Brain metastases in breast cancer. 
  • Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. 
  • Brain metastases: epidemiology. 
  • Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. 
  • Brain tumor biomarkers for research, clinics, and registries - The 2021 Brain Tumor Epidemiology Consortium meeting report. 
  • Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. 
  • Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. 
  • Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats. 
  • Brain tumors in man and animals: report of a workshop. 
  • Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). 
  • Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations. 
  • Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition? 
  • Broad immunophenotyping of the murine brain tumor microenvironment. 
  • Busulfan therapy of central nervous system xenografts in athymic mice. 
  • CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. 
  • CAR T cells and checkpoint inhibition for the treatment of glioblastoma. 
  • CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. 
  • CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. 
  • CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. 
  • CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. 
  • CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. 
  • CD155 is a putative therapeutic target in medulloblastoma. 
  • CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. 
  • CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. 
  • CNS mycosis fungoides: CT and MR findings. 
  • CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods a Southwest Oncology Group study. 
  • CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. 
  • CT scans in childhood and risk of leukaemia and brain tumours. 
  • Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. 
  • Cancer immunoediting in malignant glioma. 
  • Carboplatin pharmacokinetics in young children with brain tumors. 
  • Carotid artery injections in 40- to 99-g Fischer rats: technical note and evaluation of blood flow by various injection techniques. 
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1975. 
  • Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. 
  • Caspase 8 is absent or low in many ex vivo gliomas. 
  • Caspase-8 levels affect necessity for mitochondrial amplification in death ligand-induced glioma cell apoptosis. 
  • Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. 
  • Cellular and molecular studies in brain and nervous system oncology. 
  • Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors. 
  • Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. 
  • Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. 
  • Central nervous system extraosseous Ewing sarcoma: radiologic manifestations of this newly defined pathologic entity. 
  • Central nervous system metastases in malignant melanoma. 
  • Central neurocytoma: a review. 
  • Cerebral blood flow, blood volume, and vascular permeability of cerebral glioma assessed with dynamic CT perfusion imaging. 
  • Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. 
  • Cerebral phaeohyphomycosis mimics high-grade astrocytoma. 
  • Cerebral physiology in dogs after brain-tumor induction with Schmidt-Ruppin Rous sarcoma virus: experiences with radioiodinated normal and antiviral immunoglobulin G. 
  • Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI. 
  • Challenges to curing primary brain tumours. 
  • Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. 
  • Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. 
  • Changes in survival over time for primary brain and other CNS tumors in the United States, 2004-2017. 
  • Chaperone proteins and brain tumors: potential targets and possible therapeutics. 
  • Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. 
  • Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. 
  • Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. 
  • Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. 
  • Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy. 
  • Chemotherapy and novel therapeutic approaches in malignant glioma. 
  • Chemotherapy for adults with malignant glioma. 
  • Chemotherapy for pilocytic astrocytomas. 
  • Chemotherapy of brain tumors. 
  • Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. 
  • Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Chromosomal characteristics of childhood brain tumors. 
  • Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. 
  • Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. 
  • Classifying Leptomeningeal Disease: An Essential Element in Managing Advanced Metastatic Disease in the Central Nervous System. 
  • Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. 
  • Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical data simplified. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Clinical features of brain metastasis from salivary gland tumors. 
  • Clinical immunotherapy for brain tumors. 
  • Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. 
  • Clinical prospects for neural grafting therapy for hippocampal lesions and epilepsy. 
  • Clinical trial end points for high-grade glioma: the evolving landscape. 
  • Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. 
  • Clinicopathological characteristics and treatment of rhabdoid glioblastoma. 
  • Cognitive Implications of Ototoxicity in Pediatric Patients With Embryonal Brain Tumors. 
  • Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases. 
  • Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. 
  • Combating immunosuppression in glioma. 
  • Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. 
  • Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. 
  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. 
  • Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? 
  • Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). 
  • Commentary: A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma. 
  • Commentary: Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort. 
  • Commentary: Optimizing Postoperative Surveillance of Pediatric Low-Grade Glioma Using Tumor Behavior Patterns. 
  • Compact point-detection fluorescence spectroscopy system for quantifying intrinsic fluorescence redox ratio in brain cancer diagnostics. 
  • Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis. 
  • Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. 
  • Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. 
  • Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. 
  • Comparative permeability of different glioma models to horseradish peroxidase. 
  • Comparing the reliability of responses to telephone-administered versus self-administered Web-based surveys in a case-control study of adult malignant brain cancer. 
  • Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. 
  • Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. 
  • Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. 
  • Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. 
  • Comparison of patient age with MR imaging features of gangliogliomas. 
  • Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. 
  • Comparison of postoperative nausea between benign and malignant brain tumor patients undergoing awake craniotomy: a retrospective analysis. 
  • Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. 
  • Comparison of two head and neck immobilization systems. 
  • Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. 
  • Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. 
  • Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. 
  • Complex choristoma of the gyrus rectus: a distinct clinicopathologic entity? 
  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways. 
  • Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. 
  • Computed tomography of virally induced canine brain tumors: a preliminary report. 
  • Computer-extracted MR imaging features are associated with survival in glioblastoma patients. 
  • Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. 
  • Computerized cognitive training in survivors of childhood cancer: a pilot study. 
  • Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats. 
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. 
  • Cone-beam-CT guided radiation therapy: A model for on-line application. 
  • Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours. 
  • Conformal radiation therapy with fixed shaped coplanar or noncoplanar radiation beam bouquets: a possible alternative to radiosurgery. 
  • Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases. 
  • Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. 
  • Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. 
  • Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. 
  • Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. 
  • Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. 
  • Constrained customization of non-coplanar beam orientations in radiotherapy of brain tumours. 
  • Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. 
  • Consultative issues in surgical neuropathology: a retrospective review of the rationale for submitting cases for expert review. 
  • Continuous somatosensory evoked potential monitoring during brain tumor resection. Report of four cases and review of the literature. 
  • Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. 
  • Convection enhanced delivery of macromolecules for brain tumors. 
  • Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. 
  • Convection-enhanced delivery of therapeutics for brain disease, and its optimization. 
  • Conventional external beam radiotherapy for central nervous system malignancies. 
  • Correlated virological and ultrastructural study of Schmidt-Ruppin Rous sarcoma virus-induced dog brain tumors. 
  • Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. 
  • Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors. 
  • Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. 
  • Cortical localization of temporal lobe language sites in patients with gliomas. 
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Craniocerebral plasmacytoma: MR features. 
  • Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. 
  • Creation of an Automated Fluorescence Guided Tumor Ablation System. 
  • Criteria and definitions for response and relapse in children with brain tumors. 
  • Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. 
  • Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. 
  • Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts. 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Current multidisciplinary management of brain metastases. 
  • Current state of our knowledge on brain tumor epidemiology. 
  • Current status of adoptive immunotherapy of malignancies. 
  • Current status of therapy of solid tumors: brain tumor therapy. 
  • Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. 
  • Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen. 
  • Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. 
  • Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study. 
  • Cylindroma causing Garcin's syndrome. 
  • Cytogenetics and molecular genetics: their status and role in understanding the behavior of central nervous system neoplasms. 
  • Cytogenetics of human brain tumors. 
  • Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. 
  • DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. 
  • DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells. 
  • Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. 
  • Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. 
  • Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. 
  • Deep learning for segmentation of brain tumors: Impact of cross-institutional training and testing. 
  • Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. 
  • Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. 
  • Deletion of p16 and p15 genes in brain tumors. 
  • Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. 
  • Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells. 
  • Deletions in CCM2 are a common cause of cerebral cavernous malformations. 
  • Delivering therapy to target: improving the odds for successful drug development. 
  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. 
  • Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. 
  • Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. 
  • Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. 
  • Detecting treatment-by-centre interaction in multi-centre clinical trials. 
  • Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. 
  • Detection of cerebrospinal fluid metastasis: CT myelography or MR? 
  • Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. 
  • Development and validation of the parent experience of child illness. 
  • Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). 
  • Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. 
  • Development of novel targeted therapies in the treatment of malignant glioma. 
  • Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Diet and risk of glioma: targets for prevention remain elusive. 
  • Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. 
  • Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study. 
  • Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. 
  • Diffuse central neurocytoma with craniospinal dissemination. 
  • Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman. 
  • Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. 
  • Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. 
  • Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. 
  • Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. 
  • Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth. 
  • Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. 
  • Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. 
  • Disparities in place of death for patients with primary brain tumors and brain metastases in the USA. 
  • Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. 
  • Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. 
  • Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 
  • Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. 
  • Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. 
  • Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells. 
  • Distress persists in long-term brain tumor survivors with glioblastoma multiforme. 
  • Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. 
  • Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. 
  • Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. 
  • Does midline shift predict postoperative nausea in brain tumor patients undergoing awake craniotomy? A retrospective analysis. 
  • Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms. 
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
  • Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. 
  • Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. 
  • Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. 
  • Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. 
  • Dual-mode IVUS transducer for image-guided brain therapy: preliminary experiments. 
  • Dual-mode intracranial catheter integrating 3D ultrasound imaging and hyperthermia for neuro-oncology: feasibility study. 
  • Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. 
  • Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. 
  • Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors. 
  • Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma. 
  • EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. 
  • EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. 
  • EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • EGFRvIII as a promising target for antibody-based brain tumor therapy. 
  • EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. 
  • EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. 
  • EGFRvIII-targeted vaccination therapy of malignant glioma. 
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. 
  • Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma. 
  • Editorial for "Perfusion and Permeability Magnetic Resonance Imaging (MRI) Predicts Future Cavernous Angioma Hemorrhage and Growth". 
  • Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". 
  • Editorial: Turning fluorescence into black and white. 
  • Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 
  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. 
  • Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. 
  • Effect of glutamate analogues on brain tumor cell lines. 
  • Effect of massage therapy on stress levels and quality of life in brain tumor patients--observations from a pilot study. 
  • Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas. 
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. 
  • Effectiveness of radiotherapy for elderly patients with anaplastic gliomas. 
  • Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. 
  • Effects of therapy on the 1H NMR spectrum of a human glioma line. 
  • Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. 
  • Efficacy of MR vs CT in epilepsy. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. 
  • Electroconvulsive therapy in the presence of brain tumor. Case reports and an evaluation of risk. 
  • Ellen, a 12-year-old girl, was given a diagnosis of a primitive neuroectodermal tumor. 
  • Emerging immunotherapies for glioblastoma. 
  • Endodermal sinus tumor of the pineal region. 
  • Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. 
  • Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth. 
  • Engineering challenges for brain tumor immunotherapy 
  • Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. 
  • Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. 
  • Enhanced optical imaging of human gliomas and tumor margins. 
  • Enhanced optical imaging of rat gliomas and tumor margins. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. 
  • Enhancing Reality: A Systematic Review of Augmented Reality in Neuronavigation and Education. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. 
  • Ependymomas: MIB-1 proliferation index and survival. 
  • EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. 
  • Epidemiologic and molecular prognostic review of glioblastoma. 
  • Epidemiology and Molecular Epidemiology. 
  • Epidemiology of Brain Tumors. 
  • Epidemiology of Brain and Other CNS Tumors. 
  • Epidemiology of Intracranial Gliomas. 
  • Epidemiology of gliomas. 
  • Epidemiology of intracranial meningioma. 
  • Epidemiology of meningiomas. 
  • Epidermal growth factor receptor and variant III targeted immunotherapy. 
  • Epilepsy in neurofibromatosis type 1. 
  • Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. 
  • Establishment of patient-derived organoid models of lower-grade glioma. 
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). 
  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). 
  • Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. 
  • Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. 
  • Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. 
  • Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas. 
  • Evaluating radiation-induced white matter changes in patients treated with stereotactic radiosurgery using diffusion tensor imaging: a pilot study. 
  • Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. 
  • Evaluation of a method to measure fluorescent cell burden in complex culture systems. 
  • Evaluation of an artificial intelligence guided inverse planning system: clinical case study. 
  • Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. 
  • Evaluation of complication rates of pediatric cranial procedures in which a polyethylene glycol sealant was used. 
  • Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. 
  • Evaluation of software for registration of contrast-enhanced brain MR images in patients with glioblastoma multiforme. 
  • Evans blue nanocarriers visually demarcate margins of invasive gliomas. 
  • Everolimus tablets for patients with subependymal giant cell astrocytoma. 
  • Evidence-based Treatment for Low-grade Glioma. 
  • Evolving fetal hydranencephaly mimicking intracranial neoplasm. 
  • Evolving management of low grade glioma: No consensus amongst treating clinicians. 
  • Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. 
  • Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. 
  • ExacTrac X-ray 6 degree-of-freedom image-guidance for intracranial non-invasive stereotactic radiotherapy: comparison with kilo-voltage cone-beam CT. 
  • Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. 
  • Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. 
  • Exercise interest and preferences among patients diagnosed with primary brain cancer. 
  • Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. 
  • Experience using two CT-guided stereotactic biopsy methods. 
  • Experience with irinotecan for the treatment of malignant glioma. 
  • Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors. 
  • Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. 
  • Experimental chemotherapy of human medulloblastoma with classical alkylators. 
  • Experimental gliomas: an autoradiographic study of the endothelial component. 
  • Exploiting metabolic differences in glioma therapy. 
  • Exposure to radon and heavy particulate pollution and incidence of brain tumors. 
  • Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. 
  • Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. 
  • Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. 
  • Extending principles learned in model systems to clinical trials design. 
  • Extraneural Glioblastoma Multiforme Vertebral Metastasis. 
  • Extraskeletal myxoid chondrosarcoma of the jugular foramen. 
  • FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. 
  • FDG-PET in pediatric posterior fossa brain tumors. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. 
  • Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors. 
  • Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. 
  • Factors influencing the cell type of brain tumors induced in dogs by Schmidt-Ruppin Rous sarcoma virus. 
  • Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. 
  • False positive images in the follow-up of patients with brain tumors. 
  • False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. 
  • Familial gliomas: cases in two pairs of brothers. 
  • Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. 
  • Females have the survival advantage in glioblastoma. 
  • Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. 
  • Fibrosarcoma of the heart metastatic to the brain. 
  • Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. 
  • First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. 
  • Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma. 
  • For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. 
  • Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. 
  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. 
  • From breast to the brain: unraveling the puzzle of metastasis organotropism. 
  • GBM radiosensitizers: dead in the water…or just the beginning? 
  • GLIOGENE an International Consortium to Understand Familial Glioma. 
  • GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma. 
  • Gadolinium enhancement of the leptomeninges caused by hydrocephalus: a potential mimic of leptomeningeal metastasis. 
  • Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination. 
  • Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. 
  • Gamma Knife radiosurgery for brain metastases from gastrointestinal primary. 
  • Gamma-aminobutyric acid inhibits synergistic interleukin-6 release but not transcriptional activation in astrocytoma cells. 
  • Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. 
  • Gamma-radiation sensitivity and risk of glioma. 
  • Gamma-ray mutagen sensitivity and survival in patients with glioma. 
  • Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. 
  • Ganglioglioma: a clinical study with long-term follow-up. 
  • Gangliogliomas: characterization by registered positron emission tomography-MR images. 
  • Gd-DTPA-enhanced MR imaging of leptomeningeal spread of primary intracranial CNS tumor in children. 
  • Gender differences in facial expression recognition in survivors of pediatric brain tumors. 
  • Gene amplification in malignant human gliomas: clinical and histopathologic aspects. 
  • Gene expression profiling and genetic markers in glioblastoma survival. 
  • Gene markers in brain tumors: what the epileptologist should know. 
  • General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors. 
  • Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. 
  • Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. 
  • Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. 
  • Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. 
  • Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. 
  • Genetic variations in the homologous recombination repair pathway genes modify risk of glioma. 
  • Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. 
  • Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. 
  • Genome-wide methylation analyses in glioblastoma multiforme. 
  • Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. 
  • Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. 
  • Germline mutations in shelterin complex genes are associated with familial glioma. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Gestational trophoblastic disease metastatic to the central nervous system. 
  • Getting at the root and stem of brain tumors. 
  • Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. 
  • Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. 
  • Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015. 
  • Glioblastoma multiforme with small cell neuronal-like component: association with human neurotropic JC virus. 
  • Glioblastoma multiforme: a review of therapeutic targets. 
  • Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. 
  • Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. 
  • Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. 
  • Glioma incidence and survival variations by county-level socioeconomic measures. 
  • Glioma progression is shaped by genetic evolution and microenvironment interactions. 
  • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. 
  • Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. 
  • Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. 
  • Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. 
  • Gliomas. 
  • Gliomatosis cerebri presenting with optic nerve involvement: MRI. 
  • Gliosarcoma metastatic to the leptomeninges and dura. 
  • Global Survey of Outcomes of Neurocritical Care Patients: Analysis of the PRINCE Study Part 2. 
  • Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. 
  • Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. 
  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma. 
  • Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. 
  • Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. 
  • Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. 
  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. 
  • Grey matter edema: the marginal zone of autochthonous virally-induced gliomas. 
  • Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. 
  • Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice. 
  • Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres. 
  • HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. 
  • HER2-positive breast cancer brain metastasis: A new and exciting landscape. 
  • HIF-miR-215-KDM1B promotes glioma-initiating cell adaptation to hypoxia. 
  • Hair regrowth after cancer therapy. 
  • Hairy cell leukemia-associated familial lymphoproliferative disorder: immunologic abnormalities in unaffected family members. 
  • Hearing preservation surgery for vestibular schwannomas via the retrosigmoid transmeatal approach: surgical tips. 
  • Heart rate variability is associated with survival in patients with brain metastasis: a preliminary report. 
  • Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. 
  • Hemolytic anemia and metastatic carcinoma: case report and literature review. 
  • Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome. 
  • Heterogeneity and vascular permeability of breast cancer brain metastases. 
  • Heterotransplantation of human craniopharyngiomas in athymic "nude" mice. 
  • High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. 
  • High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. 
  • High-dose areas are unintentionally created as a result of gap shifts when the prescribed dose in the two adjacent areas are different. 
  • High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. 
  • High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. 
  • High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. 
  • High-field MR microscopy using fast spin-echoes. 
  • High-resolution mapping of heteroduplex DNA formed during UV-induced and spontaneous mitotic recombination events in yeast. 
  • High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. 
  • Hippocampal dose from stereotactic radiosurgery for 4 to 10 brain metastases: Risk factors, feasibility of dose reduction via re-optimization, and patient outcomes. 
  • How heterogeneous are gliomas? 
  • How much is enough? The question of extent of resection in glioblastoma multiforme. 
  • How parents cope with their child's diagnosis and treatment of an embryonal tumor: results of a prospective and longitudinal study. 
  • How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: equivalent uniform dose or tumor control probability? 
  • How we treat brain metastases in metastatic renal cell carcinoma. 
  • Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
  • Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. 
  • Human brain tumor xenografts. 
  • Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology. 
  • Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139). 
  • Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. 
  • Hyponatremia in pediatric patients with HIV-1 infection. 
  • Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. 
  • IDH1 and IDH2 hotspot mutations are not found in canine glioma. 
  • IDH1 and IDH2 mutations in gliomas. 
  • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 
  • IDH3α regulates one-carbon metabolism in glioblastoma. 
  • INTRACRANIAL TUMORS IN INFANCY AND CHILDHOOD. A CLINICAL STUDY OF TWENTY CASES. 
  • Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). 
  • Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. 
  • Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. 
  • Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. 
  • Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. 
  • Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. 
  • Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. 
  • Identifying new small molecule anti-invasive compounds for glioma treatment. 
  • IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. 
  • Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. 
  • Imaging descriptors improve the predictive power of survival models for glioblastoma patients. 
  • Imaging findings of structural causes of epilepsy in children: a guide for the radiologist in the emergency room. 
  • Imaging of brain tumors after administration of L-(N-13)glutamate: concise communication. 
  • Imaging of brain tumors with diffusion-weighted and diffusion tensor MR imaging. 
  • Imaging of convection enhanced delivery of toxins in humans. 
  • Immortalized hypothalamic gonadotropin-releasing hormone neurons. 
  • Immune Checkpoint Inhibitors for Brain Metastases. 
  • Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. 
  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. 
  • Immune suppression in gliomas. 
  • Immunobiologic aspects of the brain and human gliomas. A review. 
  • Immunobiology of human gliomas. 
  • Immunobiology of malignant astrocytomas. 
  • Immunobiology of primary intracranial tumors. 
  • Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. 
  • Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. 
  • Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. 
  • Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. 
  • Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs. 
  • Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. 
  • Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems. 
  • Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. 
  • Immunomodulation for glioblastoma. 
  • Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. 
  • Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy and monoclonal antibody therapies. 
  • Immunotherapy approaches for malignant glioma from 2007 to 2009. 
  • Immunotherapy approaches in the treatment of malignant brain tumors. 
  • Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? 
  • Immunotherapy for Brain Tumors. 
  • Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. 
  • Immunotherapy for primary brain tumors: no longer a matter of privilege. 
  • Immunotherapy of brain tumors. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy of surgical malignancies. 
  • Immunotherapy with tumor vaccines for the treatment of malignant gliomas. 
  • Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. 
  • Impact of collimator leaf width and treatment technique on stereotactic radiosurgery and radiotherapy plans for intra- and extracranial lesions. 
  • Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. 
  • Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. 
  • Impact of signal-to-noise on functional MRI. 
  • Implantation metastasis of primary malignant rhabdoid tumor of the brain in an adult (one case report). 
  • Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. 
  • Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. 
  • Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. 
  • Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity. 
  • In Regard to Churilla et al. 
  • In memoriam Lucien J. Rubinstein, M.D. (1924-1990). 
  • In regard to Yamamoto et al. 
  • In reply to Robins et al. 
  • In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. 
  • In vivo measurement of regional brain tissue pH using positron emission tomography. 
  • In vivo quantitation of regional cerebral blood flow in glioma and cerebral infarction: validation of the HIPDm-SPECT method. 
  • In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors. 
  • Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. 
  • Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. 
  • Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. 
  • Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. 
  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. 
  • Independent association of extent of resection with survival in patients with malignant brain astrocytoma. 
  • Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. 
  • Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. 
  • Induction of transformational changes in normal endothelial cells by cultured human astrocytoma cells. 
  • Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats. 
  • Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 
  • Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. 
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. 
  • Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. 
  • Inhibitory simple partial (non-convulsive) status epilepticus after intracranial surgery. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. 
  • Innovations in design and delivery of chemotherapy for brain tumors. 
  • Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. 
  • Integral dose conservation in radiotherapy. 
  • Intensity-modulated stereotactic radiosurgery using dynamic micro-multileaf collimation. 
  • International Differences in Treatment and Clinical Outcomes for High Grade Glioma. 
  • International practice survey on the management of brain metastases: Third International Consensus Workshop on Palliative Radiotherapy and Symptom Control. 
  • Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. 
  • Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. 
  • Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. 
  • Interstitial hyperthermia and iridium brachytherapy in treatment of malignant glioma. A phase I clinical trial. 
  • Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. 
  • Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. 
  • Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. 
  • Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. 
  • Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. 
  • Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. 
  • Intracerebral malignant melanoma: high-field-strength MR imaging. 
  • Intracerebral transplantation of a human glioma line in immunosuppressed rats. 
  • Intracranial Ewing sarcoma. 
  • Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. 
  • Intracranial atherosclerosis following radiotherapy. 
  • Intracranial dual-mode IVUS and hyperthermia using circular arrays: preliminary experiments. 
  • Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. 
  • Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. 
  • Intractable seizures, compulsions, and coprolalia: a pediatric case study. 
  • Intraoperative US versus intraoperative MR imaging for guidance during intracranial neurosurgery. 
  • Intraoperative dynamic MRI: localization of sites of brain tumor recurrence after high-dose radiotherapy. 
  • Intraoperative mapping during repeat awake craniotomy reveals the functional plasticity of adult cortex. 
  • Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. 
  • Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. 
  • Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. 
  • Introduction. 
  • Introduction. Update on adult neuro-oncology. 
  • Invasion of the internal carotid artery by cavernous sinus meningiomas. 
  • Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice. 
  • Investigational therapies for brain metastases. 
  • Iodine-125 interstitial irradiation of virally induced dog brain tumours. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Irinotecan therapy in adults with recurrent or progressive malignant glioma. 
  • Is There a Role for Immunotherapy in Central Nervous System Cancers? 
  • Is a single isocenter sufficient for volumetric modulated arc therapy radiosurgery when multiple itracranial metastases are spatially dispersed? 
  • Is cytomegalovirus a therapeutic target in glioblastoma? 
  • Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? 
  • Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. 
  • Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. 
  • Isocitrate dehydrogenase mutations in gliomas. 
  • Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. 
  • Isolation and characterization of microvessels from normal brain and brain tumors. 
  • Isolation of a human prostate carcinoma cell line (DU 145). 
  • Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. 
  • JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. 
  • L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. 
  • L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. 
  • LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. 
  • LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. 
  • LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. 
  • Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor. 
  • Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. 
  • Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. 
  • Laminin alpha 2 enables glioblastoma stem cell growth. 
  • Language outcomes after resection of dominant inferior parietal lobule gliomas. 
  • Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. 
  • Laser ablation: Heating up the anti-tumor response in the intracranial compartment. 
  • Late onset of isolated central nervous system metastasis of liposarcoma--a case report. 
  • Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. 
  • Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. 
  • Leptomeningeal failure in patients with breast cancer receiving stereotactic radiosurgery for brain metastases. 
  • Levels of stress and intervention preferences of caregivers of brain tumor patients. 
  • Leveraging external data in the design and analysis of clinical trials in neuro-oncology. 
  • Life After the Neurosurgical Ward in Sub-Saharan Africa: Neurosurgical Treatment and Outpatient Outcomes in Uganda. 
  • Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. 
  • Lin^- CCR2⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. 
  • Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. 
  • Long-Term Supratentorial Radiologic Effects of Surgery and Local Radiation in Children with Infratentorial Ependymoma. 
  • Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 
  • Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors. 
  • Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study. 
  • Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. 
  • Long-term seizure control outcomes after resection of gangliogliomas. 
  • Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? 
  • Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. 
  • Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. 
  • Loss of heterozygosity for 10q loci in human gliomas. 
  • Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. 
  • Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology. 
  • Low-grade glioma. 
  • Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. 
  • Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. 
  • Lymphocyte subpopulations and responsiveness in rats bearing intracranial tumors induced by avian sarcoma virus. 
  • Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. 
  • Lymphomatosis Cerebri: A Diagnostic Challenge. 
  • MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. 
  • MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. 
  • MR image-guided portal verification for brain treatment field. 
  • MR imaging contrast enhancement based on intermolecular zero quantum coherences. 
  • MR imaging in patients with temporal lobe seizures: correlation of results with pathologic findings. 
  • MR imaging in patients with temporal lobe seizures: correlation of results with pathologic findings. 
  • MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. 
  • MR measurement of normal and pathologic brainstem diameters. 
  • MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. 
  • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 
  • MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. 
  • MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. 
  • MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. 
  • MYCN amplification drives an aggressive form of spinal ependymoma. 
  • Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas. 
  • Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. 
  • Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. 
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. 
  • Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. 
  • Malignant glioma--timing of response to radiation therapy. 
  • Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. 
  • Management of GBM: a problem of local recurrence. 
  • Management of breast cancer brain metastases: A practical review. 
  • Management of glioblastoma in elderly patients. 
  • Management of glioblastoma: State of the art and future directions. 
  • Management of pediatric nasal dermoids with intracranial extension by direct excision. 
  • Management of pineal non-germinoma germ cell tumor with residual teratoma and normal alpha-fetoprotein. 
  • Management of postneurosurgical bone flap loss caused by infection. 
  • Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. 
  • Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. 
  • Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. 
  • Matrix Stiffness Modulates Patient-Derived Glioblastoma Cell Fates in Three-Dimensional Hydrogels. 
  • Maximizing the efficacy of angiogenesis inhibitors. 
  • Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. 
  • Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. 
  • Medical diagnostic radiation exposures and risk of gliomas. 
  • Medulloblastoma and birth date: evaluation of 3 U.S. datasets. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. 
  • Mendelian randomisation study of the relationship between vitamin D and risk of glioma. 
  • Meningeal mycosis fungoides: cytologic and ultrastructural aspects. 
  • Met and hepatocyte growth factor/scatter factor expression in human gliomas. 
  • Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. 
  • Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Metastatic carcinoma of the iris. 
  • Metastatic rhabdomyosarcoma presenting as intracranial hemorrhage: imaging findings. 
  • Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. 
  • Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. 
  • Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. 
  • Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. 
  • Microsatellite analysis of childhood brain tumors. 
  • Microsurgical management of 53 jugular foramen schwannomas: lessons learned incorporated into a modified grading system. 
  • Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. 
  • Microwave treatment of intracerebral L1210 leukemia: schedule-dependent partial reversal of the effects of methotrexate. 
  • Mimicking brain tumor-vasculature microanatomical architecture via co-culture of brain tumor and endothelial cells in 3D hydrogels. 
  • Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas. 
  • Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. 
  • Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. 
  • Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. 
  • Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. 
  • Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. 
  • Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. 
  • Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. 
  • Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. 
  • Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. 
  • Molecular imaging of a fluorescent antibody against epidermal growth factor receptor detects high-grade glioma. 
  • Molecular markers of prognosis in astrocytic tumors. 
  • Molecular pathogenesis of malignant gliomas. 
  • Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism. 
  • Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. 
  • Molecularly targeted therapy for malignant glioma. 
  • Monitoring radiographic brain tumor progression. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. 
  • Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. 
  • Monoclonal antibody therapy of human gliomas: current status and future approaches. 
  • More on surveillance of children with medulloblastoma. 
  • Morphologic and molecular genetic aspects of oligodendroglial neoplasms. 
  • Morphologic observations of brain tumors in PD4 hamsters induced by four strains of avian sarcoma virus. 
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. 
  • Mortality among autoworkers manufacturing electronics in Huntsville, Alabama. 
  • Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. 
  • Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient. 
  • Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. 
  • Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. 
  • Multidisciplinary Management of Breast Cancer Brain Metastases. 
  • Multiple fraction-per-day radiotherapy for patients with brain stem tumors. 
  • Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. 
  • Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages. 
  • Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. 
  • Mutations in CIC and FUBP1 contribute to human oligodendroglioma. 
  • Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. 
  • Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. 
  • Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. 
  • N-acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. 
  • NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. 
  • NDRG4 is required for cell cycle progression and survival in glioblastoma cells. 
  • NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma. 
  • Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. 
  • Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. 
  • National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002. 
  • National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. 
  • Neonatal neoplasms. 
  • Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. 
  • Neuro-oncology: Glioblastoma--community adjusts to new standard of care. 
  • Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? 
  • Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. 
  • Neuro-oncology: unmasking the multiforme in glioblastoma. 
  • Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier. 
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. 
  • Neurologic complications of systemic cancer. 
  • Neuropsychological effects of cranial radiation: current knowledge and future directions. 
  • Neuropsychological impact of treatment of brain tumors. 
  • Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole. 
  • Neurotologic manifestations of von Hippel Lindau disease. 
  • Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. 
  • New Approaches to Glioblastoma. 
  • New Directions in the Treatment of Glioblastoma. 
  • New therapeutic options in the management of childhood brain tumors. 
  • Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. 
  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. 
  • Non-additive and epistatic effects of HLA polymorphisms contributing to risk of adult glioma. 
  • Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Noninvasive differentiation of tumors with use of localized H-1 spectroscopy in vivo: initial experience in patients with cerebral tumors. 
  • Noninvasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging. 
  • Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. 
  • Novel Merging of CT and MRI to Allow for Safe Navigation into Kambin's Triangle for Percutaneous Lumbar Interbody Fusion-Initial Case Series Investigating Safety and Efficacy. 
  • Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. 
  • Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy. 
  • O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines. 
  • O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. 
  • Observations on the use of ferromagnetic implants for inducing hyperthermia. 
  • Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. 
  • Offer Hypofractionated SRS… If Her Performance Status Is Good. 
  • Olfactory ensheathing cell tumor: a case presentation. 
  • Oligodendroglioma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors. Case report with histological and molecular differentiation of the tumors and review of the literature. 
  • Oligodendroglioma. An analysis of the value of radiation therapy. 
  • Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. 
  • On the role of human herpesvirus 6 in viral latency in nervous tissue and in cerebral lymphoma. 
  • Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. 
  • Oncogene amplification in pediatric brain tumors. 
  • Oncogenes and anti-oncogenes in human central nervous system tumors. 
  • Operative and peri-operative considerations in the management of brain metastasis. 
  • Optimizing patient positioning for intensity modulated radiation therapy in hippocampal-sparing whole brain radiation therapy. 
  • Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 
  • Osteoblastic metastases from astrocytomas: a report of two cases. 
  • Osteogenic sarcoma of the head and neck. The UCLA experience. 
  • Our failure to advance new treatments for glioma to market. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. 
  • Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. 
  • Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma. 
  • Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. 
  • Overview of diffusion imaging. 
  • Overview of functional imaging. 
  • PET and brain tumor image fusion. 
  • PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review. 
  • PTEN gene mutations are seen in high-grade but not in low-grade gliomas. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Painful generalised clonic and tonic-clonic seizures with retained consciousness. 
  • Palliative Care Use for Critically Ill Patients With Brain Metastases. 
  • Papillary Glioneuronal Tumor With a Novel GPR37L1-PRKCA Fusion. 
  • Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. 
  • Paraneoplastic retinopathy with multiple detachments of the neurosensory retina and autoantibodies against interphotoreceptor retinoid binding protein (IRBP) in cutaneous melanoma. 
  • Parasitic lesion of the insula suggesting cerebral sparganosis: case report. 
  • Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study. 
  • Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness. 
  • Patient validation of retrospective data. 
  • Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. 
  • Patterns of Care and Age-Specific Impact of Extent of Resection and Adjuvant Radiotherapy in Pediatric Pineoblastoma. 
  • Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Patterns of exercise across the cancer trajectory in brain tumor patients. 
  • Patterns of the early, gross chromosomal changes in malignant human gliomas. 
  • Pediatric brain stem tumors: patterns of treatment failure and their implications for radiotherapy. 
  • Pediatric brain tumor patients: their parents' perceptions of the hospital experience. 
  • Pediatric brain tumors: Origins, epidemiology, and classification - The 2022 Brain Tumor Epidemiology Consortium meeting report. 
  • Peptide vaccines for the treatment of glioblastoma. 
  • Perceived social competency in children with brain tumors: comparison between children on and off therapy. 
  • Perfusion MR imaging of brain neoplasms. 
  • Pericranial flap for endoscopic anterior skull-base reconstruction: clinical outcomes and radioanatomic analysis of preoperative planning. 
  • Pericytic-like angiotropism of glioma and melanoma cells. 
  • Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. 
  • Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. 
  • Permeability of different experimental brain tumor models to horseradish peroxidase. 
  • Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Pharmacokinetics of diaziquone after three different dosage regimens. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. 
  • Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. 
  • Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. 
  • Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). 
  • Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. 
  • Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. 
  • Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. 
  • Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. 
  • Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. 
  • Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. 
  • Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. 
  • Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. 
  • Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. 
  • Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. 
  • Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. 
  • Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. 
  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. 
  • Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. 
  • Phase II study of Dovitinib in recurrent glioblastoma. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of carboplatin in children with progressive low-grade gliomas. 
  • Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). 
  • Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. 
  • Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. 
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. 
  • Phase II trial of gefitinib in recurrent glioblastoma. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. 
  • Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. 
  • Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. 
  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. 
  • Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. 
  • Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. 
  • Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. 
  • Phosphorylation of O6-alkylguanine-DNA alkyltransferase: experience with a GST-fusion protein and a new pull-down assay. 
  • Physics considerations for single-isocenter, volumetric modulated arc radiosurgery for treatment of multiple intracranial targets. 
  • Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. 
  • Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). 
  • Pilot study of the impact of massage therapy on sources and levels of distress in brain tumour patients. 
  • Pineal epidermoid cysts. 
  • Pituitary microadenoma and primary lymphoma of brain associated with hypothalamic invasion. 
  • Plasma dopamine-beta-hydroxylase in the diagnosis of neuroblastoma. 
  • Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory. 
  • Plasmonics-enhanced and optically modulated delivery of gold nanostars into brain tumor. 
  • Plug pattern optimization for gamma knife radiosurgery treatment planning. 
  • Polymorphisms of DNA repair genes and risk of glioma. 
  • Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. 
  • Poor drug distribution as a possible explanation for the results of the PRECISE trial. 
  • Positron emission tomography imaging of brain tumors. 
  • Positron emission tomography: brain tumors and lung cancer. 
  • Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population. 
  • Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. 
  • Postradiation cerebellar necrosis mimicking tumor: MR appearance. 
  • Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies. 
  • Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. 
  • Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. 
  • Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. 
  • Predicting grade of cerebral glioma using vascular-space occupancy MR imaging. 
  • Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. 
  • Pressure support mode improves ventilation in "asleep-awake-asleep" craniotomy. 
  • Presurgical detection of brain invasion status in meningiomas based on first-order histogram based texture analysis of contrast enhanced imaging. 
  • Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma. 
  • Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation. 
  • Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. 
  • Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. 
  • Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study. 
  • Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. 
  • Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water. 
  • Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. 
  • Primary central nervous system lymphoma, presenting as diabetes insipidus, as a sequela of hepatitis C. 
  • Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. 
  • Primary intracerebral Hodgkin lymphoma with recurrence. 
  • Primary intracranial Ewing's sarcoma with unusual features. 
  • Primary intracranial leiomyoma in an immunocompetent patient. 
  • Primary intracranial melanoma presenting as a suprasellar tumor. 
  • Primary spinal yolk sac tumor with brain metastasis: case report and review of the literature. 
  • Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. 
  • Profiles of brain metastases: Prioritization of therapeutic targets. 
  • Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. 
  • Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. 
  • Prognostic factors in infants and very young children with intracranial ependymomas. 
  • Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. 
  • Prognostic significance of amino acid transport imaging in patients with brain tumors. 
  • Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. 
  • Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. 
  • Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas. 
  • Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. 
  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. 
  • Program preferences to reduce stress in caregivers of patients with brain tumors. 
  • Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. 
  • Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. 
  • Promising vaccines for treating glioblastoma. 
  • Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. 
  • Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. 
  • Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. 
  • Propranolol as therapy for cerebral cavernous malformations: a cautionary note. 
  • Prospect of rindopepimut in the treatment of glioblastoma. 
  • Prospective Longitudinal Assessment of Health-related Quality of Life in Patients With Brain Metastases Undergoing Radiation Therapy. 
  • Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. 
  • Prospects of immune checkpoint modulators in the treatment of glioblastoma. 
  • Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells. 
  • Proteomic and immunologic analyses of brain tumor exosomes. 
  • Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. 
  • Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. 
  • Proton Therapy for Brain Metastases: A Question of Value. 
  • Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. 
  • Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. 
  • Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. 
  • Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. 
  • Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. 
  • Quantitative imaging of iodine-131 distributions in brain tumors with pinhole SPECT: a phantom study. 
  • Quantitative proton spectroscopy and histology of a canine brain tumor model. 
  • R-type virus-like particles in avian sarcoma virus-induced rat central nervous system tumors. 
  • RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors. 
  • Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. 
  • Racial disparities in Medicaid patients after brain tumor surgery. 
  • Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. 
  • Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. 
  • Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. 
  • Radiation treatment planning and delivery strategies for a pregnant brain tumor patient. 
  • Radiation-induced malignant gliomas: a current review. 
  • Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. 
  • Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. 
  • Radiologic-pathologic correlation. Bilateral retinoblastoma with coexistent pinealoblastoma (trilateral retinoblastoma). 
  • Radiomics Can Distinguish Pediatric Supratentorial Embryonal Tumors, High-Grade Gliomas, and Ependymomas. 
  • Radionuclide emission computed tomography of the head with 99mTc and a scintillation camera. 
  • Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+. 
  • Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. 
  • Radiosurgery is not "standard of care" for solitary brain metastases: regarding Flickinger et al., IJROBP 28:797-802; 1994. 
  • Radiosurgery treatment planning using conformal arc informed volumetric modulated arc therapy. 
  • Radiosurgery, cost-effectiveness, gold standards, the scientific method, cavalier cowboys, and the cost of hope. 
  • Radiotherapy and radiosurgery for tumors of the central nervous system. 
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. 
  • Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): a retrospective cohort study. 
  • Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. 
  • Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. 
  • Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. 
  • Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. 
  • Rathke cleft cyst intracystic nodule: a characteristic magnetic resonance imaging finding. 
  • Rational for "eight-in-one" chemotherapy. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. 
  • Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. 
  • Real-time inverse planning for Gamma Knife radiosurgery. 
  • Real-time pretreatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933. 
  • Recent advances in the treatment of pediatric brain tumors. 
  • Receptor discordance in breast cancer brain metastases: when knowledge is power. 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Recombinant Poliovirus for Cancer Immunotherapy. 
  • Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. 
  • Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. 
  • Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 
  • Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. 
  • Recurrent brain tumors in children. 
  • Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR. 
  • Recurrent intracranial Masson's vegetant intravascular hemangioendothelioma. Case report and review of the literature. 
  • Recurrent isolated sixth nerve palsy in children. 
  • Recurrent malignant gliomas. 
  • Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo. 
  • Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. 
  • Reduced antigenicity of formaldehyde-fixed arterial allografts and their potential clinical application. 
  • Refined localization of the cerebral cavernous malformation gene (CCM1) to a 4-cM interval of chromosome 7q contained in a well-defined YAC contig. 
  • Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma. 
  • Regional blood flow in avian sarcoma virus (ASV)-induced brain tumors. 
  • Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors. 
  • Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. 
  • Regional measurements of blood flow in experimental RG-2 rat gliomas. 
  • Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. 
  • Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. 
  • Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. 
  • Regulatory T cells move in when gliomas say "I Do". 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. 
  • Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma. 
  • Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. 
  • Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. 
  • Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. 
  • Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'. 
  • Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. 
  • Report of the Second International Workshop on Human Chromosome 19 mapping 1992. 
  • Resection and survival. 
  • Resection of intrinsic tumors from nondominant face motor cortex using stimulation mapping: report of two cases. 
  • Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. 
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 
  • Response assessment criteria for brain metastases: proposal from the RANO group. 
  • Response to "the epidemiology of glioma in adults: a 'state of the science' review". 
  • Response to Letter to Editor. 
  • Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. 
  • Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. 
  • Retinal vascular changes in retrograde optic atrophy. 
  • Retrospective quality metrics review of stereotactic radiosurgery plans treating multiple targets using single-isocenter volumetric modulated arc therapy. 
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. 
  • Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. 
  • Reversing the Warburg effect as a treatment for glioblastoma. 
  • RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. 
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. 
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Risk factors for childhood and adult primary brain tumors. 
  • Risk factors for oligodendroglial tumors: a pooled international study. 
  • Robust deep learning classification of adamantinomatous craniopharyngioma from limited preoperative radiographic images. 
  • Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. 
  • Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. 
  • Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. 
  • Ruptured intracranial dermoid cysts: clinical, radiographic, and surgical features. 
  • S1-nuclease enhancement of the ethidium bromide binding assay of drug-induced DNA interstrand crosslinking in human brain tumor cells. 
  • SERS nanosensors and nanoreporters: golden opportunities in biomedical applications. 
  • Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger. 
  • Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. 
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. 
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. 
  • Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. 
  • Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. 
  • Salting the Soil: Targeting the Microenvironment of Brain Metastases. 
  • Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. 
  • Sarcoidosis mimicking glioma: case report and review of intracranial sarcoid mass lesions. 
  • Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. 
  • Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. 
  • Screening for distress in patients with brain cancer using the NCCN's rapid screening measure. 
  • Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study. 
  • Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. 
  • Secondary achalasia in a patient with brainstem metastases from lung carcinoma. 
  • Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). 
  • Seesaw nystagmus following whole brain irradiation and intrathecal methotrexate. 
  • Selection of a management strategy for pediatric brainstem tumors. 
  • Selection of coplanar or noncoplanar beams using three-dimensional optimization based on maximum beam separation and minimized nontarget irradiation. 
  • Selection of patients with melanoma brain metastases for aggressive treatment. 
  • Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. 
  • Selective modification of antigen-specific T cells by RNA electroporation. 
  • Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. 
  • Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. 
  • Sequence complexity of nuclear and cytoplasmic ribonucleic acids from clonal neurotumor cell lines and brain sections of the rat. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. 
  • Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. 
  • Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. 
  • Shadow cells in an intracranial dermoid cyst. 
  • Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. 
  • Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas. 
  • Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progression. 
  • Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. 
  • Single-photon-emission computed tomographic imaging of glioma. 
  • Sinus histiocytosis with massive lymphadenopathy. Case report and review of a multisystemic disease with cutaneous infiltrates. 
  • Sluggish cognitive tempo in survivors of pediatric brain tumors. 
  • Small cell lung cancer. 
  • Small near-infrared photochromic protein for photoacoustic multi-contrast imaging and detection of protein interactions in vivo. 
  • Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. 
  • Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. 
  • Social functioning and facial expression recognition in survivors of pediatric brain tumors. 
  • Sodium and water regulation in a patient with cerebral salt wasting. 
  • Solitary eosinophilic granuloma of the temporal lobe: case report and review of the literature. 
  • Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. 
  • Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. 
  • Some structural aspects of dog brain tumors induced with the Schmidt-Ruppin strain of the Rous sarcoma virus. 
  • Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of the literature. 
  • Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas. 
  • Spatiotemporal Tracking of Brain-Tumor-Associated Myeloid Cells in Vivo through Optical Coherence Tomography with Plasmonic Labeling and Speckle Modulation. 
  • Specific chromosomal abnormalities in malignant human gliomas. 
  • Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). 
  • Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. 
  • Speckle modulation enables high-resolution wide-field human brain tumor margin detection and in vivo murine neuroimaging. 
  • Spontaneous hemorrhage associated with a pilomyxoid astrocytoma. Case report. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Staging techniques for lung cancer. 
  • Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. 
  • Standardized Brain Tumor Imaging Protocol for Clinical Trials. 
  • Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. 
  • Statin immunolocalization in human brain tumors. Detection of noncycling cells using a novel marker of cell quiescence. 
  • Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience. 
  • Stereotactic Radiosurgery for Resected Brain Metastases: New Evidence Supports a Practice Shift, but Questions Remain. 
  • Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. 
  • Stereotactic radiosurgery for recurrent malignant gliomas. 
  • Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity. 
  • Stereotactic radiosurgery in pediatric patients. 
  • Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. 
  • Stereotactic radiosurgery in the treatment of primary central nervous system lymphoma. 
  • Stress and intervention preferences of patients with brain tumors. 
  • Stress and long-term survivors of brain cancer. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. 
  • Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note. 
  • Successful therapy for trilateral retinoblastoma. 
  • Successful therapy for trilateral retinoblastoma. 
  • Successful therapy for trilateral retinoblastoma. 
  • Sulfonylurea receptor 1 expression is variable in adult and pediatric brain tumors. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. 
  • Surface antigenic characteristics of human glial brain tumor cells. 
  • Surface antigens of human glioma cells shared with normal adult and fetal brain. 
  • Surgical Management of Tumors Involving Meckel's Cave and Cavernous Sinus: Role of an Extended Middle Fossa and Lateral Sphenoidectomy Approach. 
  • Surgical approaches to pineal region tumors. 
  • Surgical management of melanoma brain metastases in patients treated with immunotherapy. 
  • Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. 
  • Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors. 
  • Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. 
  • Survival after reoperation for recurrent glioblastoma. 
  • Survival analysis of presumptive prognostic markers among oligodendrogliomas. 
  • Survival and low-grade glioma: the emergence of genetic information. 
  • Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress? 
  • Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. 
  • Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. 
  • Susceptibility of inbred Fischer rats to brain tumor induction by Rous sarcoma virus. 
  • Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. 
  • Swelling Superimposed on Atrophy Masks Optic Nerve Pathology. 
  • Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. 
  • Syndecan-1 facilitates breast cancer metastasis to the brain. 
  • Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model. 
  • Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. 
  • Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. 
  • Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. 
  • Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists. 
  • Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. 
  • Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • Systemic management of brain metastases in HER2+ breast cancer in 2022. 
  • T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. 
  • T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. 
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. 
  • TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. 
  • TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. 
  • TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 
  • Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. 
  • Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. 
  • Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion. 
  • Targeted radiotherapy for malignant gliomas. 
  • Targeted radiotherapy of brain tumours. 
  • Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. 
  • Targeting BRAF-mutant glioma: reflections on the ROAR trial. 
  • Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. 
  • Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. 
  • Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. 
  • Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration. 
  • Targeting cancer stem cells through L1CAM suppresses glioma growth. 
  • Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. 
  • Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. 
  • Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. 
  • Targeting the Tie2/Tek receptor in astrocytomas. 
  • Teaching neuroimages: vein of Galen aneurysm mimicking pineal mass in a young adult. 
  • Telomere maintenance and the etiology of adult glioma. 
  • Temozolomide and treatment of malignant glioma. 
  • Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. 
  • Temozolomide in children with progressive low-grade glioma. 
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. 
  • Temozolomide in pediatric low-grade glioma. 
  • Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. 
  • Temozolomide-induced flare in high-grade gliomas: a new clinical entity. 
  • Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. 
  • The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis. 
  • The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. 
  • The Cancer Genome Atlas expression profiles of low-grade gliomas. 
  • The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. 
  • The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. 
  • The Effects of Thermal Preconditioning on Oncogenic and Intraspinal Cord Growth Features of Human Glioma Cells. 
  • The Epidemiology of Central Nervous System Tumors. 
  • The Evolving Modern Management of Brain Metastasis. 
  • The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The Safety of available immunotherapy for the treatment of glioblastoma. 
  • The accuracy of predicting survival in individual patients with cancer. 
  • The biology of malignant gliomas--a comprehensive survey. 
  • The chemotherapy of posterior fossa tumors in childhood. 
  • The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. 
  • The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. 
  • The current landscape of immunotherapy for pediatric brain tumors. 
  • The current state of immunotherapy for gliomas: an eye toward the future. 
  • The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice. 
  • The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. 
  • The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. 
  • The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. 
  • The effect of furosemide on intravascular volume status and electrolytes in patients receiving mannitol: an intraoperative safety analysis. 
  • The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The emerging role of anti-angiogenic therapy for malignant glioma. 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The epidemiology of central and extraventricular neurocytoma in the United States between 2006 and 2014. 
  • The epidemiology of glioma in adults: a "state of the science" review. 
  • The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases. 
  • The fallacy of single-agent chemotherapy for cancer. 
  • The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus. 
  • The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. 
  • The genetic landscape of anaplastic astrocytoma. 
  • The genetic landscape of gliomas arising after therapeutic radiation. 
  • The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. 
  • The genomic landscape of familial glioma. 
  • The glioblastoma multiforme in Georgia, 1977-1981. 
  • The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. 
  • The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. 
  • The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues. 
  • The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. 
  • The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. 
  • The integrated landscape of driver genomic alterations in glioblastoma. 
  • The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. 
  • The limitations of imaging response criteria. 
  • The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. 
  • The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer. 
  • The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors. 
  • The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. 
  • The radiosurgery fractionation quandary: single fraction or hypofractionation? 
  • The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. 
  • The role of chemotherapy in the treatment of central neurocytoma. 
  • The role of patient primary language in access to brain tumor resection: Evaluating emergent admission and hospital volume. 
  • The role of social support in families coping with childhood brain tumor. 
  • The role of surgery for patients with metastatic melanoma. 
  • The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats. 
  • The role of tregs in glioma-mediated immunosuppression: potential target for intervention. 
  • The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. 
  • The role of whole brain radiation therapy in the management of melanoma brain metastases. 
  • The somatic genomic landscape of glioblastoma. 
  • The surgical management of metastatic melanoma. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • The trilateral retinoblastoma syndrome. 
  • The use of G-CSF during craniospinal irradiation. 
  • The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. 
  • The use of fluorescein sodium in the biopsy and gross-total resection of a tectal plate glioma. 
  • The use of motor mapping to aid resection of eloquent gliomas. 
  • Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. 
  • Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. 
  • Therapeutic analysis of in vitro and in vivo brain tumor models. 
  • Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. 
  • Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. 
  • Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. 
  • Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. 
  • Therapeutic profile of the human glioma line D-54 MG in athymic mice. 
  • Therapeutic strategies to improve drug delivery across the blood-brain barrier. 
  • There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. 
  • Three IMRT advanced planning tools: A multi-institutional side-by-side comparison. 
  • Thyroid neoplasia following irradiation for medulloblastoma: report of two cases. 
  • Time to Steroid Independence After Laser Interstitial Thermal Therapy vs Medical Management for Treatment of Biopsy-Proven Radiation Necrosis Secondary to Stereotactic Radiosurgery for Brain Metastasis. 
  • Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. 
  • Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. 
  • Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. 
  • Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. 
  • Total dietary antioxidant index and survival in patients with glioblastoma multiforme. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Transciliary orbitofrontozygomatic approach to lesions of the anterior cranial fossa. 
  • Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. 
  • Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials. 
  • Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. 
  • Treatment of Gliomas: A Changing Landscape. 
  • Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. 
  • Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete? 
  • Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke. 
  • Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids. 
  • Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report. 
  • Treatment of central nervous system xenografts with camptothecins. 
  • Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. 
  • Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. 
  • Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. 
  • Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. 
  • Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. 
  • Treatment of patients with pineoblastoma with high dose cyclophosphamide. 
  • Treatment of patients with recurrent primary brain tumors with AZQ. 
  • Treatment of radiation-induced nervous system injury with heparin and warfarin. 
  • Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Trilateral retinoblastoma: clinical and radiologic progression. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. 
  • Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. 
  • Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. 
  • Tumor progression and transformation of low-grade glial tumors associated with pregnancy. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. 
  • Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. 
  • Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). 
  • Tumors of the central nervous system. Improvement in outcome through a multimodality approach. 
  • Twenty-year survival in glioblastoma: a case report and molecular profile. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. 
  • Understanding the Genetic Risk of IDH-Mutant Glioma. 
  • Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. 
  • Unusual presentations of fetal teratoma. 
  • Unusual presentations of inflammatory conditions in cerebrospinal fluid. 
  • Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. 
  • Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors. 
  • Use of apparent diffusion coefficient values for diagnosis of pediatric posterior fossa tumors. 
  • Use of bevacizumab in recurrent glioblastoma. 
  • Use of quinones in brain-tumor therapy: preliminary results of preclinical laboratory investigations. 
  • Use of whole body hyperthermia as a method to heat inaccessible tumours uniformly: a phase III trial in canine brain masses. 
  • Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. 
  • Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. 
  • Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. 
  • Vaccination strategies for neuro-oncology. 
  • Vaccine-based immunotherapeutic approaches to gliomas and beyond. 
  • Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. 
  • Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. 
  • Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. 
  • Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. 
  • Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. 
  • Vascular-targeted photothermal therapy of an orthotopic murine glioma model. 
  • Vasoactive drugs produce selective changes in flow to experimental brain tumors. 
  • Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. 
  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. 
  • Virus-cell relationships in dog brain tumors induced with Schmidt-Ruppin Rous sarcoma virus. 
  • Virus-induced experimental brain tumors and putative associations of viruses with human brain tumors: a review. 
  • Viruses and oncogenes in brain tumors. 
  • Viruses as therapeutic agents against malignant disease of the central nervous system. 
  • Viruses in the treatment of brain tumors. 
  • Viruses in the treatment of malignant glioma. 
  • Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. 
  • Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas. 
  • Volume effect in paediatric brain tumour resection surgery: analysis of data from the Japanese national inpatient database. 
  • Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. 
  • Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. 
  • Volumetric-modulated arc therapy: effective and efficient end-to-end patient-specific quality assurance. 
  • Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. 
  • What is New in Neuro-oncology? 
  • What is your patient's GPA and why does it matter? Managing brain metastases and the cost of hope. 
  • When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis. 
  • White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. 
  • Who benefits from surgery for brain metastases? 
  • Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. 
  • Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. 
  • Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. 
  • Work exposures to animal neurocarcinogens. 
  • Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. 
  • Working memory training in survivors of pediatric cancer: a randomized pilot study. 
  • Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. 
  • Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. 
  • [Benzodiazepine receptors of the mouse glioblastoma cell line: the anomalous effect of gamma-aminobutyric acid on diazepam binding]. 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
  • [New type of specific binding sites for gamma-aminobutyric acid (GABA) found in a mouse glioblastoma]. 
  • [Significance of monoclonal antibodies in diagnosis and therapy of tumors of the central nervous system]. 
  • c-Myc is required for maintenance of glioma cancer stem cells. 
  • miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. 
  • p53 gene alterations in human prostate carcinoma. 
  • αB-crystallin: a novel regulator of breast cancer metastasis to the brain. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • O'Daniel, Jennifer Colleen, Assistant Professor of Radiation Oncology, Radiation Oncology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology